

7. LITERATURVERZEICHNIS

1. American Heart Association. Heart Disease and Stroke Statistics: 2005 Update. Dallas, Texas: American Heart Association (2005)
2. Applied Biosystems GmbH: User Bulletin #2 for ABI PRISM 7700 Sequence Detection System (1997)
3. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H et al.: Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. *Nat.Med.* 8, 35-40 (2002)
4. Baker AH, Zaltsman AB, George SJ, Newby AC: Divergent effects of tissue inhibitor of metalloproteinase-1, -2, -3 overexpression on rat vascular smooth muscle cell invasion, proliferation and death in vitro: TIMP-3 promotes apoptosis. *J.Clin.Invest.* 101, 1478-1487 (1998)
5. Bambi B, Eghbali M: Effect of norepinephrine on myocardial collagen gene expression and response of cardiac fibroblasts after norepinephrine treatment. *Am.J.Pathol.* 139, 1131-1142 (1991)
6. Bashey RI, Donnelly M, Insinga F, Jiminez SA: Growth factor properties and biochemical characterization of collagens synthesized by adult rat heart fibroblasts in culture. *J.Moll.Cell.Cardiol.* 24, 691-700 (1992)
7. Birkedal-Hansen H: Matrix Metalloproteinases: A Review. *Crit.Rev.Oral Biol.Med.* 4, 197-250 (1993)
8. Böhm M, Kouchi I, Schnabel P, Zolk O: Transition from hypertrophy to failure -  $\beta$ -adrenergic desensitization of the heart. *Heart Failure Rev.* 4, 329-351 (1999)
9. Boluyt MO, O'Neill L, Meredith AL, Bing OHL, Brooks WW, Conrad CH, Crow MT, Lakatta EG: Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure. *Circ.Res.* 75, 23-32 (1994)
10. Border WA, Noble A: Transforming growth factor  $\beta$  in tissue fibrosis. *N Engl.J.Med.* 331, 1286-1292 (1994)
11. Bosman FT, Stamenkovic I: Functional structure and composition of the extracellular matrix. *J.Pathol.* 200, 423-428 (2003)

12. Bouzeghrane F, Thibault G: Is angiotensin II a proliferative factor in cardiac fibroblasts? *Cardiovasc.Res.* 53, 304-312 (2002)
13. Brand T, Schneider MD: The TGF $\beta$  superfamily in myocardium: ligands, receptors, transduction and function. *J.Mol.Cell.Cardiol.* 27, 5-18 (1995)
14. Brooks WW, Conrad CH: Myocardial fibrosis in transforming growth factor heterozygous mice. *J.Mol.Cell.Cardiol.* 32, 187-195 (2000)
15. Brown RD, Ambler SK, Mitchell MD, Carlin SL: The Cardiac Fibroblast: Therapeutic Target in Myocardial Remodeling and Failure. *Annu.Rev.Pharmacol.Toxicol.* 45, 657-687 (2005)
16. Bustin SA: Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. *J.Mol.Endo.* 25, 169-193 (2000)
17. Casscells W, Bazoberry F, Speir EH, Thompson NL, Flanders KC, Kondaiah P, Ferrans VJ, Epstein SE, Sporn MB: Transforming growth factor beta1 in normal heart and in myocardial infarction. *Ann.NY Acad.Sci.* 593, 148-160 (1990)
18. Chomczynski P, Sacchi N: Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction. *Anal.Biochem.* 162, 156-159 (1987)
19. Chua CC, Chua BH, Zhao ZY, Krebs C, Diglio C, Perrin E: Effect of growth factors on collagen metabolism in cultured heart fibroblasts. *Connect.Tissue Res.* 26, 271-281 (1991)
20. Chua CC, Diglio CA, Siu BB, Chua BH: Angiotensin II induces TGF-beta1 production in rat heart endothelial cells. *Biochem.Biophys.Acta* 1223, 141-147 (1994)
21. Ciulla MM, Paliotti R, Esposito A, Diez J, Lopez B, Dahlöf B, Nicholls G, Smith RD et al.: Different effects of antihypertensive therapies based on Losartan and atenolol on ultrasound and biochemical markers of myocardial fibrosis. *Circulation* 110, 552-557 (2004)
22. Crawford D, Chobanian A, Brecher P: Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat. *Circ.Res.* 74, 727-739 (1994)
23. Delcayre C, Silvestre J: Aldosterone and the heart: towards a physiological function? *Cardiovasc.Res.* 43, 7-12 (1999)

24. Dostal DE: Regulation of cardiac collagen: angiotensin and cross talk with local growth factors. *Hypertension* 37, 841-844 (2001)
25. Eghbali M, Tomek R, Sukhatme VP, Woods C, Bambi B: Differential effects of transforming growth factor  $\beta$ 1 and phorbol myristate acetate on cardiac fibroblasts: regulation of fibrillar collagen mRNAs and expression of early transcription factors. *Circ.Res.* 69, 483-490 (1991)
26. Eghbali M, Weber KT: Collagen and the myocardium: fibrillar structure, biosynthesis and degradation in relation to hypertrophy and its progression. *Mol.Cell.Biochem.* 96, 1-14 (1990)
27. Engelhardt S, Hein L, Wiesmann F, Lohse MJ: Progressive hypertrophy and heart failure in beta-1-adrenergic receptor transgenic mice. *Proc.Natl.Acad.Sci.USA* 96, 7059-7064 (1999)
28. Everett AD, Tufro-McReddie A, Fisher A, Gomez RA: Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression. *Hypertension* 23, 587-592 (1994)
29. Fisher SA, Absher M: Norepinephrine and angiotensin II stimulate secretion of TGF-beta by neonatal rat cardiac fibroblasts in vitro. *Am.J.Physiol.* 268, C910-C917 (1995)
30. Gao MH, Lai NC, Roth DM, Zhou J, Zhu J, Anzai T, Dalton N, Hammond HK: Adenylyl cyclase increases responsiveness to catecholamine stimulation in transgenic mice. *Circulation* 99, 1618-1622 (1999)
31. Gray MO, Long CS, Kalinyak JE, Li HT, Karliner JS: Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. *Cardiovasc.Res.* 40, 352-363 (1998)
32. Greene J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE: Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. *J.Biol.Chem.* 271, 30375-30380 (1996)
33. Haeuseler C, Flesch M, Amann K, Schlüter KD, Rosenkranz S: Entwicklung von Myokardhypertrophie und Alteration der  $\beta$ -adrenergen Signaltransduktion in TGF- $\beta$ 1-transgenen Mäusen. *Z Kardiol.* 89(Suppl.5), 213 (2000)

34. Hall MC, Young DA, Waters JG, Rowan AD, Chantry A, Edwards DR, Clark IM: The comparative role of activator protein 1 and Smad factors in the regulation of TIMP-1 and MMP-1 gene expression by transforming growth factor-beta 1. *J.Biol.Chem.* 278, 10304-10313 (2003)
35. Hao J, Wang B, Jones SC, Jassal DS, Dixon IMC: Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vivo. *Am.J.Physiol.Heart Circ.Physiol.* 279, H3020-3030 (2000)
36. Heimer R, Bashey RI, Kyle J, Jiminez SA: TGF $\beta$  modulates the synthesis of proteoglycans by myocardial fibroblasts in culture. *J.Mol.Cell.Cardiol.* 27, 2191-2198 (1995)
37. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Macioni DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). *Circulation* 112 (12), 1825-1852 (2005)
38. Huse M, Chen YG, Massague J, Kuriyan J: Crystal structure of the cytoplasmatic domain of the type I TGF $\beta$  receptor in complex with FKBP12. *Cell* 96, 426-436 (1999)
39. Iizuka K, Sano H, Kawaguchi H, Kitabatake A: Transforming growth factor  $\beta$ 1 modulates the number of  $\beta$ -adrenergic receptors in cardiac fibroblasts. *J.Mol.Cell.Cardiol.* 26, 435-440 (1994)
40. Iwase M, Uechi M, Vatner DE, Asai K, Shannon RP, Kudej RK, Wagner TE, Wight DC, Patrick TA, Ishikawa Y, Homcy CJ, Vatner SF: Cardiomyopathy induced by cardiac G<sub>s</sub>-alpha overexpression. *Am.J.Physiol.* 272, H585-H589 (1997)
41. Jugdutt BI: Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways. *Curr. Drug Targets Cardiovasc. Haematol. Disord.* 3, 1-30 (2003)
42. Junqueira LC, Bignolas G, Brentani RR: Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. *Histochem.J.* 11, 447-455 (1979)

43. Kannel WB, Belanger AJ: Epidemiology of heart failure. *Am. Heart J.* 121, 951-197 (1991)
44. Kannel WB: Vital epidemiologic clues in heart failure. *J.Clin.Epidemiol.* 53, 229-235 (2000)
45. Kanzaki T, Olofsson A, Moren A Wernstedt C, Hellman U, Miyazono K, Cleasson-Welsh L, Heldin CH: TGF $\beta$ 1 binding protein: a compound of the large latent complex of TGF $\beta$ 1 with multiple repeat sequences. *Cell* 61, 1051-1061 (1990)
46. Kim S, Ohta K, Hamaguchi A et al.: Angiotensin II type 1 receptor antagonist inhibits the gene expression of TGF $\beta$ 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. *J.Pharmacol.Exp.Ther.* 273, 509-515 (1995)
47. Kimura M, Ogihara M: Transforming growth factor beta-1 inhibits the growth of primary hepatocyte cultures by increasing cAMP levels. *Eur.J.Pharmacol.* 386, 271-277 (1999)
48. Knauper V, Murphy G: Membrane-type matrix metalloproteinases and cell surface-associated activation cascades for matrix metalloproteinases. In: Parks WC, Mecham RP, eds.: *Matrix Metalloproteinases*. San Diego, CA: Academic Press, 199-218 (1998)
49. Komuro IYK, Hoh E, Takaku F, Yazaki Y: Mechanisms of cardiac hypertrophy and injury – possible role of protein kinase C activation. *Jpn.Circ.J.* 55, 1149-1157 (1991)
50. Kupfahl C, Pink D, Friedrich K, Zurbrugg HR, Neuss M, Warnecke C, Fielitz J, Graf K, Fleck E, Regitz-Zagrosek V: Angiotensin II directly increases transforming growth factor beta-1 and osteopontin and indirectly affects collagen mRNA expression in human heart. *Cardiovas.Res.* 46, 463-475 (2000)
51. Kuwahara F, Kai H, Tokuda K: Transforming growth factor  $\beta$  function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. *Circulation* 160, 130-135 (2002)
52. Li RK, Mickle DA, Weisel RD, Merante F, Luss H, Rao V, Christiakis GT, Williams WG: Overexpression of transforming growth factor  $\beta$ 1 and insulin-like growth factor 1 in patients with idiopathic hypertrophic cardiomyopathy. *Circulation* 96, 874-881 (1997)

53. Li YY, Feldman AM, Sun Y, McTiernan CF: Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. *Circulation* 98, 1728-1734 (1998)
54. Li YY, McTiernan CF, Feldman AM: Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. *Cardiovasc.Res.* 42, 162-172 (1999)
55. Ligett SB, Tepe NM, Lorenz JN, Canning AM, Jantz TD, Mitarai S, Yatani A, Dorn GW: Early and delayed consequences of  $\beta$ 2-adrenergic receptor overexpression in mouse hearts. *Circulation* 101, 1707-1714 (2000)
56. Lijnen PJ, Petrov VV: Antagonism of the renin-angiotensin-aldosterone system and collagen metabolism in cardiac fibroblasts. *Meth.Find Clin.Pharm.* 21, 215-227 (1999)
57. Lijnen PJ, Petrov VV, Fagard RH: Induction of Cardiac Fibrosis by Transforming Growth Factor- $\beta$ 1, *Mol. Gen. and Metabol.* 71, 418-435 (2000)
58. Lijnen PJ, Petrov VV: Role of intracardiac renin-angiotensin-aldosterone system in extracellular matrix remodeling. *Meth.Find.Exp. Clin.Pharmacol.* 25, 541-564 (2003)
59. Lim H, Zhu YZ: Role of transforming growth factor- $\beta$  in the progression of heart failure. *Cell.Mol.Life.Sci.* 63, 2584-2596 (2006)
60. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin Phenol Reagent. *J.Biol.Chem.* 193, 265-275 (1951)
61. Mac Kenna DA, Omens JH, McCulloch AD et al.: Contribution of collagen matrix to passive left ventricular mechanics in isolated rat hearts. *Am.J.Physiol.* 266, H1007-H1018 (1994)
62. Masoudi FA, Havranek EP, Krumholz HM: The burden of chronic congestive heart failure in older persons: magnitude and implications for policy and research. *Heart Fail Rev.* 7, 9-16 (2002)
63. Massague J, Wotton D: Transcriptional control by the TGF $\beta$ / Smad signaling system. *EMBO J.* 19, 1745-1754 (2000)
64. Massague J: TGF $\beta$  signal transduction. *Ann.Rev.Biochem.* 67, 753-791 (1998)
65. McDonnell S, Morgan M, Lynch C: Role of matrix metalloproteinases in normal and disease processes. *Biochem.Soc.Trans.* 27, 734-740 (1999)

66. Milano CA, Allen LF, Rockman HA, Dolber PC, McMinn TR, Chien KR, Johnson TD, Bond RA, Lefkowitz RJ: Enhanced myocardial function in transgenic mice overexpressing the  $\beta_2$ -adrenergic receptor. *Science* 264, 582-586 (1994)
67. Monzen K, Hiroi Y, Kudoh S et al.: Smads, TAK1 and their common target ATF-2 play a critical role in cardiomyocyte differentiation. *J.Cell.Biol.* 153, 687-698 (2001)
68. Moriguchi Y, Matsubara H, Mori Y: Angiotensin II-induced transactivation of epidermal growth factor receptor regulates fibronectin and transforming growth factor beta synthesis via transcriptional and posttranscriptional mechanisms. *Circ.Res.* 84, 1073-1084 (1999)
69. Morrison TB, Weis JJ, Wittwer CT: Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. *Biotechniques* 24, 585-588 (1998)
70. Nagase H: Activation mechanisms of matrix metalloproteinases. *Biol.Chem.* 378, 151-160 (1997)
71. Nakajima H, Nakajima HO, Salcher O, Dittie AS, Dembowsky K, Jing S, Field LJ: Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor  $\beta_1$  transgene in the heart. *Circ.Res.* 86, 571-579 (2000)
72. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. *J.Clin.Oncol.* 18, 1135-1149 (2000)
73. Nogami M, Romberger DJ, Rennard SI, Toews ML: TGF $\beta_1$  modulates  $\beta$ -adrenergic receptor number and function in cultured human tracheal smooth muscle cells. *Am.J.Physiol.* 266, L187-L191 (1994)
74. Parameshwar J, Keegan J, Sparrow J, Sutton GC, Poole-Wilson PA: Predictors of prognosis in severe heart failure. *Am.Heart J.* 123, 421-426 (1992)
75. Parker TG, Packer SE, Schneider MD: Peptide growth factors can provoke fetal contractile protein gene expression in rat cardiac myocytes. *J.Clin.Invest.* 85, 507-514 (1990 [1])
76. Pauschinger M, Knopf D, Petschauer S, Doerner A, Poller W, Schwimmbeck PL, Kühl U, Schultheiss HP: Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. *Circulation* 99, 2750-2756 (1999)

77. Perlouch V, Dixon IHC, Golfman L, Meamish RE, Dhalla NS: Role of extracellular matrix protein in heart function. *Mol.Cell.Biochem.* 129, 101-120 (1994)
78. Piek E, Heldin CH, Ten Dijke P: Specificity, diversity and regulation in TGF $\beta$  superfamily signaling. *FASEB J.* 13, 2105-2124 (1999)
79. Puchtler H, Waldrop FS, Valentine LS: Polarization Microscopic Studies of Connective Tissue Stained with Picro-Sirius Red FBA. *Beitr.Path.* 150, 174-187 (1973)
80. Ririe KM, Rasmussen RP, Wittwer CT: Product differentiation analysis of DNA melting curves during the polymerase chain reaction. *Anal.Biochem.* 245, 154-160 (1997)
81. Roberts AB, Sporn MB: Physiological actions and clinical applications of transforming growth factor beta. *Growth Factors* 8, 1-9 (1993)
82. Rodriguez-Pena A, Prieto M, Duwel A, Rivas JV, Eleno N, Perez-Barriocanal F, Arevalo M et al.: Up-regulation of endoglin, a TGF-beta-binding protein, in rats with experimental renal fibrosis induced by renal mass reduction. *Nephrol.Dial.Transplant.* 16 Supp. 1, 34-39 (2003)
83. Rosenkranz S, Amann K, Caglayan E, Teimann K, Schlüter KD, Koteliansky V, Bäumer AT:  $\beta$ -adrenoceptor-blockade prevents cardiac hypertrophy and failure in TGF- $\beta$  transgenic mice. *Eur.J.Heart* 24(Suppl.(Abstract)): 665 (2003)
84. Rosenkranz S, Flesch M, Amann K, Haeuseler C, Kilter H, Seeland U, Schlüter KD, Böhm M: Alterations of  $\beta$ -adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF $\beta$ 1. *Am.J.Physiol.* 283, H1253-1262 (2002)
85. Rosenkranz S, Flesch M, Haeuseler C, Amann K, Kilter H, Schlüter KD: Cardiac hypertrophy und alterations of  $\beta$ -adrenergic signaling in transgenic mice overexpressing TGF- $\beta$ 1. *Circulation* (Suppl.), 102, II-71 (2000)
86. Rosenkranz S: TGF $\beta$ 1 and angiotensin networking in cardiac remodeling. *Cardiovasc.Res.* 63, 423-432 (2004)
87. Rossi MA: Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronical hypertension in humans. *J.Hypertens.* 16, 1031-1041 (1998)

88. Runyan CE, Schnaper HW, Poncelet AC: Smad3 and PCK delta mediate TGF-beta1-induced collagen I expression in human mesangial cells. *Am.J.Physiol.Renal Physiol.* 285, F413-422 (2003)
89. Sadoshima J, Izumo S: Molecular characterisation of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT<sub>1</sub> receptor. *Circ.Res.* 73, 413-423 (1993)
90. Samuel SK, Hurta RA, Kondaiah P, Khalil N, Turley EA, Wright JA, Greenberg AH: Autocrine induction of tumor protease production and invasion by a metallothionein-regulated TGF- $\beta_1$ . *EMBO J.* 11, 1599-1605 (1992)
91. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, Roberts AB, Sporn MB, Thorgeirsson SS: Hepatic expression of mature transforming growth factor  $\beta_1$  in transgenic mice results in multiple tissue lesions. *Proc.Natl.Acad.Sci. USA* 92, 2572-2576 (1995)
92. Sappino AP, Schürch W, Gabbiani G: Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as markers of phenotypic modulations. *Lab. Invest.* 85, 507-514 (1990)
93. Schiller M, Javelaud D, Mauviel A: TGF $\beta$ -induced Smad signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing. *J. Derm.Sci.* 35, 83-92 (2004)
94. Schlunegger MP, Grutter MG: An unusual feature revealed by the crystal structure at 2.2 Å resolution of human transforming growth factor-beta. *Nature* 358, 430-434 (1992)
95. Schlüter KD, Zhou XJ, Piper HM: Induction of hypertrophic responsiveness to isoproterenol by TGF $\beta$  in adult rat cardiomyocytes. *Am.J.Physiol.* 269, C1311-1316 (1995)
96. Schorb W, Booz GW, Dostal DE, Conrad KM, Chang KC, Baker KM: Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. *Circ.Res.* 72, 1245-1254 (1993)
97. Schultz JEJ, Witt SA, Glascock BJ: TGF $\beta_1$  mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. *Clin.Invest.* 109, 787-796 (2002)

98. Seeland U, Haeuseler C, Hinrichs R, Rosenkranz S, Pfitzner T, Scharffetter-Kochanek K, Böhm M: Myocardial fibrosis in TGF $\beta$ <sub>1</sub>-transgenic mice is associated with inhibition of interstitial collagenase. *Eur.J.Clin.Invest.* 32, 295-303 (2002)
99. Song H, Foster AH, Conte JV, Chi-Ming W: Presentation and localization of transforming growth factor beta isoforms and its receptor subtypes in human myocardium in the absence and presence of heart failure. *Circulation* 96, SI: I-362 (1997)
100. Spiale FG: Matrix Metalloproteinases: Regulation and Dysregulation in the Failing Heart. *Circ.Res.* 90, 520-530 (2002)
101. Sporn MB, Roberts AB: The transforming growth factor-betas: past, present and future. *Ann.NY Acad.Sci.* 593, 1-6 (1990)
102. Sun Y, Zhang JQ, Zhang J, Ramires FJ: Angiotensin II, transforming growth factor beta-1 and repair in infarcted heart. *J.Moll.Cell.Cardiol.* 8, 1559-1569 (1998)
103. Sweat F, Puchtler H, Rosenthal SI: Sirius Red F3BA as stain for connective tissue. *Archs Pathology* 78, 69-72 (1964)
104. Takahashi N, Calderone A, Izzo NJ, Maki TM, Marsh JD, Colucci W: Hypertrophic stimuli induce transforming growth factor beta-1 expression in rat ventricular myocytes. *J.Clin.Invest.* 94, 1470-1476 (1994)
105. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ III, Spinales FG: Increased matrix metalloproteinase and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. *Circulation* 97, 1708-1715 (1998)
106. Thompson NL, Bazoberry F, Speir EH, Casscells W, Ferrans VJ, Flanders KC, Kondaiah P, Geiser AG, Sporn MB: Transforming growth factor beta1 in acute myocardial infarction in rats. *Growth Factors* 1, 91-99 (1988)
107. Tokuda K, Kai H, Kuwahara F et al.: Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis. *Hypertension* 43, 499-503 (2004)
108. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA: Myofibroblasts and mechano-regulation of connective tissue remodeling. *Nat.Rev.Mol.Cell.Biol.* 3, 349-363 (2002)

109. Tomita H, Egashira K, Ohara Y et al.: Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long term blockade of nitric oxide synthesis in rats. *Hypertension* 32, 273-279 (1998)
110. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL: SARA, a FYVE domain protein that recruits Smad2 to the TGF $\beta$  receptor. *Cell* 95, 779-791 (1998)
111. Tyagi SC, Campbell SE, Reddy HK, Tjahja E, Voelker DJ: Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts. *Mol.Cell.Biochem.* 155, 13-21 (1996)
112. van Wamel AJ, Ruwhof C, van der Valk-Kokshoom LJM, Schrier A, van der Laarse A: Stretch-induced paracrine hypertrophic stimuli increase TGF $\beta_1$  expression in cardiomyocytes. *Mol.Cell.Biochem.* 236, 147-153 (2002)
113. Villareal FK, Dillmann WH: Cardiac hypertrophy-induced changes in mRNA levels for TGF $\beta_1$ , fibronectin and collagen. *Am.J.Physiol.* 262, H1861-1866 (1992)
114. Villareal FK, Lee AA, Dillmann WH, Giordano FJ: Adenovirus-mediated overexpression of human transforming growth factor  $\beta_1$  in rat cardiac fibroblasts, myocytes and smooth muscle cells. *J.Mol.Cell.Cardiol.* 28, 735-724 (1996)
115. Wachtell K, Okin PM, Olsen MH, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE et al.: Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden death: the LIFE-study. *Circulation* 116, 700-705 (2007)
116. Wada H, Zile MR, Ivester CT, Cooper IV G, McDermott PJ: Comparative effects of contraction and angiotensin II on growth of adult feline cardiocytes in primary culture. *Am.J.Physiol.* 271, H29-37 (1996)
117. Weber KT, Janicki JS, Schroff SG, Pick R, Chen RM, Bashey RI: Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. *Circ.Res.* 62, 757-765 (1988)
118. Wenzel S, Taimor G, Piper HM, Schlüter KD: Redox-sensitive intermediates mediate angiotensin II-induced p38 MAP kinase activation, AP-1 binding activity and TGF $\beta$  expression in adult ventricular cardiomyocytes. *FASEB J.* 15, 2291-2291 (2001)

119. White HD, Norris RM, Brown MA, Brandt PWT, Whitlock RML, Wild CJ: Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. *Circulation* 76, 44-51 (1987)
120. Woessner JF Jr., Nagase H: Activation of the zymogen forms of MMPs. In: *Matrix Metalloproteinases and TIMPs*. New York, NY: Oxford University Press, 72-86 (2000)
121. Woessner JF Jr., Nagase H: Introduction to the matrix metalloproteinases (MMPs). In: *Matrix Metalloproteinases and TIMPs*. New York, NY: Oxford University Press, 1-10 (2000)
122. Woessner JF Jr.: The matrix metalloproteinase family. In: Parks WC, Mecham RP, eds. *Matrix Metalloproteinases*. San Diego, CA: Academic Press, 1-14 (1998)
123. Wong C, Rougier-Chapman EM, Frederick JP, Datto MB, Leberati NT, Li JM, Wang F: Smad3-Smad4 and AP-1 complexes synergize in transcriptional activation of c-Jun promoter by transforming growth factor-beta. *Mol.Cell.Biol.* 19, 1812-1830 (1999)
124. Wu Y, Cazorla O, Labeit D et al.: Changes in titin and collagen underlie diastolic stiffness diversity of cardiac muscle. *J.Mol.Cell.Cardiol.* 32, 2151-2162 (2000)
125. Wünsch M, Sharma HS, Markert T: In situ localization of transforming growth factor  $\beta_1$  in porcine heart: enhanced expression after chronic coronary artery occlusion. *J.Mol.Cell.Cardiol.* 23, 1051-1062 (1991)
126. Yamamoto K, Masuyama T, Sakata Y et al.: Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. *Cardiovasc.Res.* 55, 76-82 (2002)
127. Zannad F, Radauceanu A: Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure. *Heart Failure Rev.* 10, 71-78 (2005)
128. Zhang D, Gaussion V, Taffet GE et al.: TAK-1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. *Nat.Med.* 6, 556-563 (2000)
129. Zhang Y, Feng XH, Derynck R: Smad3 and Smad 4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription. *Nature* 394, 909-913 (1998)

## KAPITEL 7 - LITERATURVERZEICHNIS

130. Zou Y, Komuro I, Yamazaki T et al.: Cell-type specific angiotensin II-evoked signal transduction pathways: critical roles of G<sub>Bγ</sub> subunit, Src family and Ras in cardiac fibroblasts. *Circ.Res.* 82, 337-345 (1998)